MCC
CRSP icon

Money Concepts Capital’s CRISPR Therapeutics CRSP Stock Holding History

Money Concepts Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,738
Closed -$225K – 640
2026
Q1 		$225K Buy
+4,738
New +$250K 0.01% 521
2025
Q3 		– Sell
-4,885
Closed -$238K – 474
2025
Q2 		$238K Buy
+4,885
New +$189K 0.02% 405
2023
Q1 		– Sell
-4,118
Closed -$167K – 960
2022
Q4 		$167K Buy
4,118
+150
+4% +$7.96K 0.01% 765
2022
Q3 		$259K Buy
3,968
+3,912
+6,986% +$284K 0.02% 384
2022
Q2 		$4K Sell
56
-205
-79% -$12.1K ﹤0.01% 1200
2022
Q1 		$16K Buy
+261
New +$16.4K ﹤0.01% 1706

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Money Concepts Capital's CRSP Position: Q2 2026 in Review

Money Concepts Capital sold out of CRISPR Therapeutics (CRSP) in Q2 2026, closing a stake of 4,738 shares — an estimated $225K sold.

Money Concepts Capital first reported a position in CRSP in Q1 2022 and held it in 6 quarters. The position peaked at $259K in Q3 2022. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Money Concepts Capital reported no remaining CRISPR Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Money Concepts Capital sold 4,738 CRISPR Therapeutics shares in Q2 2026, an estimated $225K.
  • Money Concepts Capital first reported a position in CRISPR Therapeutics in Q1 2022 and held it in 6 quarters.
  • Money Concepts Capital's CRISPR Therapeutics position peaked at $259K in Q3 2022.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Money Concepts Capital's 13F filing for Q2 2026, filed 4 Aug 2026.